StockData
Clene Inc. logo

Clene Inc. (CLNN) company profile

CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$3.22−0.44 (-12.02%)

Close on Nov 17, 2026Market cap $41.37MP/E –Yield –

About Clene

Pharmaceutical Preparations, SIC 2834

This clinical-stage pharmaceutical company develops clean-surfaced nanotechnology therapeutics designed to treat neurodegenerative diseases and central nervous system disorders, including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease. Its proprietary platform synthesizes stable, highly catalytic nanocrystals from transition elements without toxic organic residues. The company's lead drug asset is an orally administered gold nanocrystal suspension engineered to restore cellular energy metabolism, increase intracellular adenosine triphosphate production, and reduce oxidative stress and toxic protein aggregates. Additional pipeline candidates in early development include ionic solutions for infectious diseases and wound healing. It also markets mineral dietary supplements, either directly through a subsidiary or via licensing partnerships with supplement distributors.

The company operates its clinical research programs across various healthcare centers within the United States and has conducted long-term clinical trial extensions in Australia. In addition to its clinical pipeline, the company distributes commercial dietary supplements internationally through a licensing partner. The company's corporate headquarters and executive offices are not stated in the provided text.

Summary of the business section of Clene's latest annual report, written by StockData.

Company profile

Company

Legal name
Clene Inc.
Headquarters
Salt Lake City, UT
Address
6550 South Millrock Drive, Suite G50 84121
Phone
(801) 676-9695
Website
clene.com
Employees
79, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Salt Lake City, Utah

Stock & identifiers

Ticker
CLNN
Exchange
Nasdaq
IPO date
Oct 18, 2018
Shares outstanding
13M, Aug 11, 2026
Public float
$40.40M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Jul 11, 2024
SEC CIK
1822791
CUSIP
185634201
ISIN
US1856342019
FIGI
BBG00X3GTK66
Share class FIGI
BBG00X3GTK84
EIN
85-2828339

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert Dee EtheringtonPresident & CEO, Director57,279
Mark MortensonChief Science Officer28,949
Morgan R. BrownChief Financial Officer0
Alison MoscaDirector703,974
Arjun JJ DesaiDirector16,298
Vallerie McLaughlinDirector–
Reed N. WilcoxDirector575,145
Matthew KiernanDirector8,540
Jonathon GayDirector2,329,218
Shalom JacobovitzDirector20,838
David J. MatlinDirector919,775

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Robert Etherington
President and Chief Executive Officer
$508.76K$386.15K$38.48K$933.39K-32%
Mark Mortenson
Chief Science Officer
$412.02K$368.36K$29.05K$809.43K-25%
Morgan R. Brown
Chief Financial Officer
$292.58K$163.49K$31.59K$487.65K-36%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 79 employees, 76 of which were full-time and 3 were part-time, primarily located in Utah and Maryland.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?